All News

price%20of%20pills.jpg

ACR Speaks Against Repeated Cuts to Medicare Reimbursements

d ACR

The American College of Rheumatology has submitted its comments to the CMS regarding the proposed CY 2025 Medicare Physician Fee Schedule and Quality Payment Program rule and its impact on rheumatologists and rheumatology interprofessional team members’ ability to provide care to the 53 million Americans living with rheumatic disease.

Read Article
pregnancy,embryo,fetal

Low Placental Transfer Rates with Risankizumab

d Jack Cush, MD

There are significant concerns about the safety of drug use during pregnancy and lactation, especially newer biologic agents. This is complicated by a lack of research. 

Read Article
ACR, guidance, guidelines

ACR Recommends QOL Self-Management Strategies

d ACR

American College of Rheumatology (ACR) experts identified research suggesting that patient self-management is not a

Read Article
Methotrexate

Consensus Guidelines on Pediatric Methotrexate Use

d Jack Cush, MD

Methotrexate (MTX) is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects.

Read Article
Hand%20squeeze.jpg

Moving Forward on RA Prevention Trials

d Jack Cush, MD

Now that multiple prevention clinical trials for rheumatoid arthritis (RA) have been completed, a group of investigators have reviewed the results and published their recommendations for future trial designs and drug development to assess interventions that may alter disease development.

Read Article
Fracture.spine_.op_.jpg (keep)

Conservative Treatment of Acute Vertebral Fractures

d Jack Cush, MD

A network meta-analysis of pain outcomes in patients with acute osteoporotic vertebral compression fractures (VCFs) showed short-term success with calcitonin and NSAIDs in decreasing pain during activity, but long-term benefits were superior for teriparatide compared to bisphosphonates.

Read Article
In elderly onset rheumatoid arthritis, Treg cells are increased, but have decr suppressor activity. Maybe due to elevated Type I IFN with IFN-β suppressing old Tregs and increasing PD-1 expression. https://t.co/51ww481FkJ https://t.co/8EA1fENaFm

Links:

Dr. John Cush RheumNow ( View Tweet)
CA-125 & PET/CT screening in 1432 myositis. 125 pts had CA-125 w/in 5yrs of onset - 3.1% false-positives (fibroids, endometriosis) & 14.3% false-negatives. 139 had PET done- 5.5% false-positives (LN, lung nodules), 28.6% false-negatives (missed melanoma, breast or prostate CA)… https://t.co/16KSDmp9Kz https://t.co/6QFl4jhDxp
Dr. John Cush RheumNow ( View Tweet)
French retrospective study of 181 hemodialysis pts (97 on urate Rx-90% allopurinol, 9% febuxostat). W/ ULT pts had significantly fewer agout flare (HR:0.42; CI 95: 0.25-0.71). Overall flares 35% (23% ULT vs 50% w/o ULT; p 0.0002) https://t.co/9hTgsR2Kx9 https://t.co/Bef0T1po2c

Links:

Dr. John Cush RheumNow ( View Tweet)
Linger on the Fingers (9.6.2024) Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. This week with a focus on fingers and better prescriptive follow through. https://t.co/c9yvRjE9av https://t.co/mdN37AWHjX

Links:

Dr. John Cush RheumNow ( View Tweet)
Claims analysis of two datasets showed TNFi treatment in 1st two years after newly Dx breast cancer (n 2216) had no effect on overall survival (OS); but had signif better breast cancer survival (HR 0.28; 0.08–0.98) vs csDMARD Rx. Pts on GC worse OS (HR 2.18)… https://t.co/Kxk7Sy7ahi https://t.co/PtxRsTifi1
Dr. John Cush RheumNow ( View Tweet)
post hoc analysis of 4432 pt COLCORONA trial, showed colchicine had few drug interactions, none serious. The most common were interactions w/ rosuvastatin & atorvastatin (10-12% of all pts), that MAY nonsignificantly increase colchicine exposure https://t.co/W3JXne0ywH https://t.co/dNz6NVYjUW

Links:

Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study 69 Systemic Sclerosis Pts: 33% w/ PPI-refractory esophagitis & 2/3 w/ EGD normal esophageal mucosa. PPI-refractory esophagitis was more commonly linked to diffuse SSc subset (43 vs 17%) and GI dysmotility (66 vs 8%; p = <0.001) https://t.co/givt90C0tE https://t.co/3oN5qUHpUU

Links:

Dr. John Cush RheumNow ( View Tweet)
CAR-T Like Effects with Bispecific Teclistamab A new chapter may have begun in the exciting story of "immune reset" therapy for difficult-to-treat autoimmune diseases, with a patient with severe refractory lupus obtaining drug-free remission after treatment with an antibody… https://t.co/uE7QEHc0nx https://t.co/UcenZHv35O
Dr. John Cush RheumNow ( View Tweet)
Does Rheumatoid Factor Influence Anti-TNF Responses in RA? Smolen and colleagues have published a subanalysis of the EXXELERATE study that showed while certolizumab pegol [CZP] concentrations and efficacy was unaffected by high titers of rheumatoid factor (RF), patients treated… https://t.co/Ux9gHXcGbv https://t.co/gpcuWrqVHi
Dr. John Cush RheumNow ( View Tweet)
While Raynaud's phenomenon severity is worst at very cold temperatures, it may also worsen during very warm temperatures, presumably due to air conditioning. Based on q3mos assessments of 2243 RP pts (88% female, 82% White, mean 55 yrs https://t.co/4c0XzqHYjB https://t.co/TOn4DJP4Xi

Links:

Dr. John Cush RheumNow ( View Tweet)
Urticarial Vasculitis Overview Urticarial vasculitis is rare and the causes often go undiagnosed. A Medscape recent overview highlights key features in the diagnosis and management of this rare disorder. https://t.co/TUlCw76asZ https://t.co/HwDQpsAtws

Links:

Dr. John Cush RheumNow ( View Tweet)
EMA Updated overview of leflunomide (Arava) https://t.co/LbuqzDdTvf https://t.co/npfsRDdFiP

Links:

Dr. John Cush RheumNow ( View Tweet)
Good Clinical Practice Recommendations on Glucocorticoid Withdrawal and Adrenal Insufficiency The European Society of Endocrinology and Endocrine Society have jointly published a clinical guideline on the diagnosis and treatment of glucocorticoid-induced adrenal insufficiency,… https://t.co/GmQ5ypvqWP https://t.co/oab9qHpxSa
Dr. John Cush RheumNow ( View Tweet)
Sustained Hydroxychloroquine and Cardiovascular Outcomes A national cohort study shows that continuous use of hydroxychloroquine (HCQ) protects against cardiovascular (CV) events in patients with systemic lupus erythematosus (SLE). https://t.co/xqB2tyzzYQ https://t.co/dlFjbgbsep

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×